Multiple myeloma (MM) is a cancer characterized by the accumulation of plasma cells in the bone marrow (BM). It remains an incurable disease due to the development of drug resistance, of which the BM microenvironment (consisting of supporting cell types like BM stromal cells (BMSCs)) and the low amounts of oxygen (= hypoxia) play a crucial role in. However, little is known about how these two components influence each other. To find new targets for therapy, I aim to investigate which metabolic changes are induced in the cancer cells by hypoxia, but also in the surrounding cell types as both components influence each other extensively.

This study will investigate the following objectives: (1) Examine the influence of a hypoxic environment on disturbed metabolic pathways, (2) Examine the influence of BMSC-derived hypoxic exosomes on MM cell metabolism and vice versa, (3) Targeting metabolic
pathways as novel therapy to conquer drug resistance. The ceramide, proline and glutamine pathways are the main pathways of interest. Experiments will be performed in vitro on human and murine cell lines, accompanied by confirmation on patient samples and in vivo on mice. This research will contribute to expand the current
state-of-the-art on how drug resistance develops and can be blocked, as well as identify crucial metabolic changes that form potential targets for new therapies. I aim to identify at least one potent metabolic inhibitor that limits drug resistance.
Effective start/end date1/10/1931/10/21

    Flemish discipline codes

  • Cell signalling
  • Hematology
  • Cellular interactions and extracellular matrix
  • Cancer biology
  • Cancer therapy

    Research areas

  • Multiple Myeloma, hypoxic BM, metabolic changes

ID: 47892274